| BNF Section/s |
Title |
Issuing Body |
Date of Issue |
Update Due |
| 4.2.1 |
Antiepileptic Drugs -Guidance for prescribing antiepileptic drugs
|
MHRA
Drug Safety Update
|
Nov 2017 |
- |
| 4.2.1 |
Antiepileptic drugs: - Updated advice on switching between different manufacturers’ products
|
MHRA
Drug Safety Update
|
Nov 2017 |
- |
| 4.3.6 / 4.1 |
Antipsychotics - Reviewing Antipsychotics prescribed for Behavioral and Psychological Symptoms of Dementia(BPSD) in Primary Care
|
Kent & Medway CCG
|
Mar 2022 |
Mar 2024 |
| 4.2.1 /4.3 /4.7.1 |
|
Medway CCG |
Oct 2018 |
- |
| 4.2.1 /4.3 /4.7.1 |
Benzodiazepines & Controlled Drugs - Controlled drugs/benzodiazepine prescribing patient treatment
agreement |
Kent & Medway CCG |
Apr 2022 |
Apr 2024 |
| 4.6.2 |
Botulinum toxin - Botulinum toxin type A and calcitonin gene-related peptide inhibitors for preventing migraine in adults |
NHS Kent & Medway |
Aug 2022 |
Aug 2024 |
| 4.4.1 |
Botulinum toxin - Botulinum toxin type A for facial lines |
Kent & Medway PRGC |
Feb 2015 |
- |
| 4.4.1 |
Botulinum toxin - Botulinum toxin for spasticity in adults |
Kent & Medway PRGC |
May 2016 |
- |
| 4.2.1 |
Brivaracetam - Brivaracetam Prescribing
|
Kent & Medway CCG |
Dec 2021 |
Dec 2023
|
| 4.2.1 |
Cenobamate - Cenobamate for treating focal onset seizures in epilepsy TA753
|
NICE |
Dec 2021 |
- |
| 4.2.1 |
Cenobamate - Cenobamate Prescribing Guidance |
NHS Kent & Medway ICB |
Aug 2022 |
Aug 2024 |
| 4.4.1 |
Chloral Hydrate - Position Statement for - Off label use of Chloral Hydrate in the Management of Intrusive Movement and Motor Disorders in Children and Young People |
Kent & Medway CCG |
Apr 2022 |
Apr 2024 |
| 4.7.1 |
Chloral Hydrate - Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication |
MHRA
Drug Safety Update
|
Oct 2021 |
- |
| 4.7.1 |
Daridorexant - Daridorexant Prescribing Guidance |
Kent & Medway ICB
|
Mar 2024 |
|
| 4.7.1 |
Daridorexant - Daridorexant for treating long-term insomnia TA922
|
NICE
|
Oct 2023 |
|
| 4.1 |
Dementia - Dementia Medication Prescribing Guideline V6.2 |
Kent & Medway ICB
& KMPT
|
Oct 2023 |
Oct 2025 |
| 4.5.1 |
Domperidone: risks of cardiac side effects
|
MHRA
Drug Safety Update
|
Dec 2014 |
- |
| 4.6.2 |
Eptinezumab (Vyepti®)
ICB commissioned - approval via Blueteq
|
High-Cost Drugs |
|
|
| 4.6.2 |
Eptinezumab (Vyepti®) - Eptinezumab for preventing migraine TA871
|
NICE |
Mar 2023 |
- |
| 4.6.2 |
Erenumab (Aimovig®)
ICB commissioned approval via Blueteq
|
High-Cost Drugs |
|
|
| 4.6.2 |
Erenumab (Aimovig®) - Erenumab for preventing migraine TA682 |
NICE |
Mar 2021 |
- |
| 4.6.2 |
Fremanezumab (Ajovy®)
ICB commissioned approval via Blueteq |
High-Cost Drugs |
|
|
| 4.6.2 |
Fremanezumab (Ajovy®) - Fremanezumab for preventing migraine TA764 |
NICE |
Feb 2022 |
|
| 4.6.2 |
Galcanezumab (Emgality®)
ICB commissioned approval via Blueteq
|
High-Cost Drugs |
|
|
| 4.6.2 |
Galcanezumab (Emgality®) - Galcanezumab for preventing migraine TA659 November 2020 |
NICE |
Nov 2020 |
|
| 4.3.4 / 4.3.6 |
KMPT Formulary |
- |
- |
- |
| 4.6.3 |
Lidocaine Plasters -Position Statement Prescribing Lidocaine Plasters 5% (700mg) |
Kent & Medway CCG |
Sep 2021 |
Sep 2023
|
| 4.7.1 |
Melatonin - Melatonin for Jet lag |
Kent & Medway PRGC |
Mar 2021 |
- |
| 4.7.1 |
Melatonin -Guideline on the Use of Melatonin for the Management of Sleep Disorders in Children, Adolescents, and Adults Version 1.1 |
Kent & Medway ICB |
Dec 2023 |
Dec 2025 |
| 4.7.1 |
Melatonin - Melatonin Prescribing Checklist |
Kent & Medway ICB
|
Apr 2024 |
Apr 2026 |
| 4.5.1 |
Metoclopramide: risk of neurological adverse effects
|
MHRA
Drug Safety Update
|
Aug 2013 |
- |
| 4.6.2 |
Migraine/Headaches - Management of Adults with Headaches and Migraines in Primary Care
|
Kent & Medway ICB |
Aug 2022 |
Aug 2024 |
| 4.6.2 |
Migraine -Adult Chronic & Episodic Migraine Referral Form
|
Kent & Medway ICB |
Aug 2022 |
Aug 2024 |
| 4.6.1.2 |
Morphine - Actimorph Patient Information 1mg/2.5mg/5mg/10mg/20mg/30mg |
- |
Jan 2023 |
- |
4.6 /
4.6.1.2 |
Morphine - Position Statement on prescribing Liquid Morphine Sulfate in Kent & Medway |
Kent & Medway ICB |
Oct 2023 |
Oct 2025 |
4.6 /
4.6.1.2 |
Morphine - Morphine Liquid Appropriate Use Guidance |
Kent & Medway ICB |
Oct 2023 |
Oct 2025 |
| 4.6 |
Opioids - Kent and Medway CCG Position Statement on Opioid Prescribing |
Kent & Medway CCG |
Apr 2022 |
Apr 2024 |
| 4.6 |
Opioids - Guidance to Support the Safe and Effective, Initiation and Review of Opioids |
Kent & Medway ICB |
Feb 2023 |
Feb 2025 |
| |
|
|
|
|
| 4.6 |
Opioids -Opioid Tapering Resource Pack Chronic non-cancer pain in adults |
Kent & Medway CCG |
Apr 2022 |
Apr 2024 |
| 4.2.1 |
Perampanel - Perampanel Prescribing Guidance
|
Kent & Medway ICB |
Aug 2022 |
Aug 2024 |
| 4.6.2 |
Rimegepant - Rimegepant Prescribing Guideline for Primary Care Version 1.1 |
Kent & Medway ICB |
Jun 2024 |
Jun 2026 |
| 4.6.2 |
Rimegepant - Rimegepant for preventing migraine TA906 |
NICE |
Jul 23 |
- |
| 4.6.2 |
Rimegepant - Rimegepant for treating migraine NICE Guidance TA919 |
NICE |
Oct 23 |
_ |
| 4.2.1 |
Sodium Valproate - Sodium Valproate pathway for GP reviews and referral to specialists 2019 |
MFT Drug & Therapeutic Committee/ Medway & Swale CCG |
Jan 2020 |
- |
|
4.6.2
4.2.1
|
Topiramate - Topiramate – Implementing MHRA Safety Measures in Kent & Medway V1.2 |
Kent & Medway ICB |
Nov 2024 |
- |
|
4.3.3
4.2.1
|
Valproate - Valproate Medicines Pregnancy Prevention Programme |
MHRA
Drug Safety Update
|
May 2018 |
- |
|
4.3.3
4.2.1
|
Valproate - Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme |
MHRA
Drug Safety Update
|
April 19 |
- |
